Evogene (NASDAQ:EVGN – Get Free Report) is expected to issue its Q3 2026 results before the market opens on Thursday, November 19th. Analysts expect the company to post earnings of ($0.19) per share and revenue of $0.36 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 19, 2026 at 9:00 AM ET.
Evogene Stock Up 5.6%
EVGN stock opened at $0.39 on Tuesday. The stock’s 50 day simple moving average is $0.41 and its 200 day simple moving average is $0.63. Evogene has a 12-month low of $0.25 and a 12-month high of $1.26.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evogene in a report on Friday, October 2nd. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has an average rating of “Sell”.
Read Our Latest Analysis on Evogene
About Evogene
Evogene Ltd. is an Israel-based computational biology company founded in 2002. It uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and computational tools, to discover and develop products for agriculture, human health and other life-science applications. The company advances its work through subsidiaries and collaborations. Its businesses have included Casterra, which develops castor seed varieties, and Lavie Bio, which develops microbiome-based agricultural products.
Featured Stories
- Five stocks we like better than Evogene
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
